TRANSMISSIBLE GASTROENTERITIS VIRUS (TGEV)
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Moderately effective: Requires high level of compliance with extraordinary on-farm biosecurity measures to prevent farm-to-farm transmission; Easy: Distinct clinical signs and/or existing test(s) available at local/regional laboratory(s); Moderate: Manageable losses related to endemic (population) or chronic (individual) occurrence; Negligible: Little or no market disruption when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); Available but uncertain efficacy: Commercial or autogenous vaccines exist in the US but protection may be inconsistent; Difficult and uncertain: Extremely difficult and with uncertain success rate, few global examples of success even at farm level
OVERVIEW
Transmissible gastroenteritis virus (TGEV) is an alphacoronavirus causing highly contagious enteric disease in swine, first described in the United States in 1946. The disease is characterized by vomiting, severe watery diarrhea, and near-100% mortality in piglets under 2 weeks of age. The emergence and widespread prevalence of PRCV (a naturally occurring deletion mutant) since the 1980s has significantly reduced TGE's clinical impact through partial cross-protection, though sporadic outbreaks continue in both TGEV/PRCV seronegative and seropositive herds across North America, Europe, and Asia. TGEV co-circulates with PEDV in many regions, and recombinant TGEV/PEDV variants (SeCoV) have been identified in Europe, adding complexity to the epidemiological landscape.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
Pigs are the main species naturally susceptible to TGEV and PRCV. No infection of humans through food consumption has been reported despite decades of endemic circulation and extensive human exposure in production settings. While novel canine-feline-swine spike recombinant alpha-CoVs closely related to TGEV have been identified in human illness cases (CCoV-HuPn-2018, HuCCoV-Z19), these represent distinct recombinant viruses with canine coronavirus backbones rather than TGEV itself, and foodborne transmission has not been implicated in any of these cases.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
No human infections with TGEV have been documented despite decades of occupational exposure in swine production settings worldwide. The virus shows strong host specificity for pigs. The recently identified canine-feline-swine recombinant alpha-CoVs associated with human pneumonia or febrile illness have a CCoV-IIb backbone and represent distinct evolutionary events involving multiple animal coronaviruses rather than direct TGEV zoonosis. Standard occupational contact with TGEV-infected pigs does not pose infection risk to workers.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Moderately effective: Requires high level of compliance with extraordinary on-farm biosecurity measures to prevent farm-to-farm transmission
TGEV is highly photosensitive and inactivated by sunlight within 6 hours, which limits environmental persistence outdoors compared to many other pathogens. However, the virus persists in liquid manure for over 8 weeks at 5°C and remains infectious in water and sewage for weeks at 4°C, creating indirect transmission opportunities. Starlings and houseflies have been proposed as mechanical vectors, and cats, dogs, and foxes can shed virus in feces for variable periods after exposure. Wild boar show approximately 30% seroprevalence in Central Europe, suggesting wildlife involvement in maintenance. These pathways provide some transmission routes beyond standard biosecurity, though fecal-oral contact and direct pig-to-pig transmission remain the dominant routes in modern production systems.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Easy: Distinct clinical signs and/or existing test(s) available at local/regional laboratory(s)
Multiple validated diagnostic approaches exist for TGEV. Real-time RT-PCR assays readily detect and differentiate TGEV from PRCV, PEDV, PDCoV, and SADS-CoV using primers targeting the S gene deletion region. Immunofluorescence and immunohistochemistry using monoclonal antibodies detect viral antigen in intestinal tissues. ELISA formats detect antigens in feces and intestinal contents. Virus isolation in ST cells or pig kidney cells is routine in diagnostic laboratories. Blocking ELISAs differentiate TGEV from PRCV antibodies at the herd level, though interpretation requires consideration of vaccination history. The clinical presentation—acute vomiting, severe watery diarrhea, and high neonatal mortality spreading rapidly through susceptible herds—combined with readily available multiplex diagnostics makes detection and confirmation straightforward.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Moderate: Manageable losses related to endemic (population) or chronic (individual) occurrence
In epidemic outbreaks in seronegative herds, mortality approaches 100% in piglets under 2 weeks of age, with lactating sows developing agalactia that compounds piglet losses through starvation. However, the widespread prevalence of PRCV has dramatically reduced TGE's clinical impact since the 1980s by providing partial cross-protective immunity in most swine populations. Endemic TGE causes lower mortality (under 10-20%) in partially immune herds where maternal antibodies provide initial protection. The disease is self-limiting once herd immunity develops through natural infection. Current sporadic outbreaks cause significant but localized losses rather than industry-wide catastrophic impact.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Negligible: Little or no market disruption when disease occurs on one or more farms
TGEV is endemic worldwide and does not trigger trade restrictions between major swine-producing nations. The disease has been present globally since 1946 and is not an OIE-listed disease affecting international market access. Outbreaks cause on-farm economic losses that are absorbed at the producer level but do not result in movement restrictions, export bans, or consumer concern about food safety. Unlike foreign animal diseases such as ASF or FMD, TGEV detection does not trigger regulatory responses affecting markets. Consumer awareness is essentially zero, and pork from recovered animals poses no food safety concerns.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
TGEV is a viral pathogen. The virus itself poses no antimicrobial resistance concerns as it does not carry, acquire, or disseminate antimicrobial resistance determinants. While secondary bacterial infections may occur in TGEV-affected herds requiring antimicrobial treatment, the primary pathogen contributes nothing to the AMR gene pool or resistance dissemination.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
No antiviral treatments exist for TGEV, so disease management does not involve antimicrobials targeting the causative agent. Antibacterial therapy may be beneficial in 2-5-week-old pigs with concurrent bacterial infections complicating recovery, but antimicrobials are not routinely used for uncomplicated TGE cases. Treatment focuses on supportive care: maintaining warm environments above 32°C, providing water and electrolytes, and cross-fostering piglets to immune sows with good milk production. The self-limiting nature of outbreaks and reliance on lactogenic immunity rather than antimicrobial intervention means TGEV infections generate minimal selection pressure for antimicrobial resistance.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
No antiviral drugs have been developed for TGEV treatment. RNA interference approaches and interferon-based strategies showed some promise in laboratory cell culture studies but have not translated to practical in vivo therapies for field use. Management is entirely supportive: maintaining environmental temperature above 32°C, providing fluids to combat dehydration, preventing secondary bacterial infections, and ensuring piglets have access to immune sows. These supportive measures can reduce mortality in pigs infected after 3-4 days of age when some physiological maturity has developed, but do not treat the underlying viral infection. Oral electrolyte therapy is actually contraindicated in very young pigs due to limited intestinal absorptive capacity. The focus remains entirely on prevention through lactogenic immunity rather than post-infection treatment.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: Available but uncertain efficacy: Commercial or autogenous vaccines exist in the US but protection may be inconsistent
Several licensed TGEV vaccines exist in both inactivated and live attenuated formulations for use in pregnant sows or neonatal pigs. However, parenteral vaccines induce poor gut mucosal immunity and fail to prevent agalactia or stimulate protective IgA secretion into milk. Only oral administration of live virulent virus consistently stimulates the lactogenic immunity pathway with secretory IgA antibodies appearing in colostrum and milk. Attenuated vaccine strains show limited intestinal replication in immunocompetent sows, reducing their ability to prime mucosal immune responses. The presence of maternal antibodies interferes with active immunization of piglets, limiting direct piglet vaccination strategies. Current commercial vaccines are most effective for boosting immunity in previously infected or exposed herds rather than initiating protection in fully naive animals. The widespread industry practice of "feedback"—intentional exposure to virulent virus from infected intestinal contents—reflects the practical limitations of available commercial vaccines for naive herd protection.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Difficult and uncertain: Extremely difficult and with uncertain success rate, few global examples of success even at farm level
TGEV can be eliminated from infected herds without depopulation through coordinated management strategies: simultaneous controlled exposure of all breeding animals to establish uniform immunity, strict all-in/all-out production flow to break transmission cycles, and monitoring with sentinel pigs to confirm elimination. Several successful herd-level eliminations have been documented in the literature. However, population-level eradication across the US swine industry faces substantial challenges: the virus persists in wild boar populations at significant seroprevalence rates, potential wildlife reservoirs including carnivores may maintain transmission, and the widespread endemic distribution of PRCV complicates seroprevalence interpretation and surveillance efforts. The dramatic decline in TGEV prevalence following PRCV emergence demonstrates that natural ecological factors can substantially reduce disease burden, but complete eradication would require sustained coordinated effort across the entire swine industry including addressing wildlife reservoirs.